News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Ram’s appointment follows the launch of the CDI India division in October 2021.
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Subscribe To Our Newsletter & Stay Updated
